Continuous Monitoring of Prostate Position During Radiotherapy (KIM Gating)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01742403|
Recruitment Status : Recruiting
First Posted : December 5, 2012
Last Update Posted : April 5, 2018
|Condition or disease||Intervention/treatment||Phase|
|Prostate Cancer||Radiation: R/T gating kV intrafraction monitoring||Not Applicable|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||100 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase I Feasibility Study of Prostate Cancer Radiotherapy Gating Using kV Intrafraction Monitoring (KIM)|
|Study Start Date :||January 2013|
|Estimated Primary Completion Date :||December 2018|
|Estimated Study Completion Date :||June 2019|
Experimental: R/T gating kV intrafraction monitoring
Intervention: Recruitment will be performed in 2 phases:
Phase I will include the first 10 patients. All patients will be treated on a standard fractionation protocol with 40 fractions. This will allow 400 potential fractions to be auto-segmented in real time. Once Phase I is successfully completed we will aim to continue recruitment of a further 20 patients as Phase II. For this phase we will open recruitment to patients with lymph node positivity, hypofractionation (as per Department protocols) and intermittent imaging (imaging less frequently than every fraction).
Radiation: R/T gating kV intrafraction monitoring
This is a Phase I Pilot study to assess the feasibility of implementing prostate radiotherapy gating using kV intrafraction monitoring.
- Feasibility [ Time Frame: 2 years ]Technique will be determined as feasible if 90% of treatment fractions are successfully segmented in real time.
- Time for procedure [ Time Frame: 2 years ]Measurement of time taken to perform KIM gating to guide future department resource questions.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01742403
|Contact: Thomas N Eade, MBBS||+61294631319||TEade@nsccahs.health.nsw.gov.au|
|Contact: Jeremy Booth, PhD||+61294631320||JBooth@nsccahs.health.nsw.gov.au|
|Australia, New South Wales|
|Department of Radiation Oncology, Northern Sydney Cancer Centre||Recruiting|
|St. Leonards, New South Wales, Australia, 2065|
|Contact: Thomas N Eade, MBBS +61294631315 Thomas.Eade@health.nsw.gov.au|
|Contact: Clare Banks, MPH +61 2 9463 1345 Clare.Banks@health.nsw.gov.au|
|Principal Investigator: Thomas N Eade, RANZCR I & II|
|Principal Investigator:||Thomas Eade, MBBS||Royal North Shore Hospital|